ArticleMediterranean journal of rheumatology2025
Assessment of Cognitive Impairment in Rheumatoid Arthritis.
Article in Mediterranean journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The objectives of our study were to assess the prevalence of cognitive impairment in Rheumatoid arthritis (RA) and to identify its predictive factors. Methods: A 6-month cross-sectional case-control study englobing patients with RA was carried out. The cognitive evaluation was performed using the Mini Mental State Examination (MMSE), the frontal efficiency battery, the 5-word test, the clock drawing test and the Trail Making Test part-A (TMT-A). Linear regression analyses were conducted to identify predictors of cognitive impairment. Results: We included 35 RA patients and 35 controls. Concerning the RA group, the mean duration of the disease was 12.3 years [1-29 years]. RA was immunopositive in 80% of cases and erosive in 83% of cases. The global cognitive dysfunction assessed by MMSE score was 49%. Depending on the test used, the prevalence of cognitive impairment in RA ranged from 34% to 54%. RA patients presented poorer results regarding the TMT-A than the controls (p = 0.03). The other cognitive tests were comparable between the 2 groups. The main predictive independent factors of cognitive impairment among RA patients were advanced age (p = 0.002), rural environment (p = 0.007), low income (p = 0.01), recent course of RA (p = 0.006), low disease activity (p = 0.002) and low blood sugar (p = 0.003). Conclusion: Global cognitive impairment in RA concerned 49% of our patients. Early identification of the factors associated with this cognitive dysfunction is necessary in order to improve the quality of life of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.